ZVRA
What one share of Zevra Therapeutics holds
Pharmaceutical Preparations
We are a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. We are focused on expanding patient access, progressing our pipeline toward key milestones, and delivering meaningful therapeutics.
Zevra Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.28 |
|---|---|
| Profit | $0.96 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | $0.55 |
| Cash and investments | $2.45 |
| Debt | $0.00 |
| Book value | $3.67 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$1.13 | $0.04 | −$2.08 | — | −$1.28 |
| 2017 | — | −$2.96 | $0.01 | −$2.27 | — | −$3.92 |
| 2018 | $0.00 | −$3.15 | $0.00 | −$3.02 | — | — |
| 2019 | $6.93 | −$13.23 | $0.01 | −$12.82 | — | −$32.77 |
| 2020 | $3.34 | −$3.21 | $0.01 | −$0.50 | — | −$14.64 |
| 2021 | $0.96 | −$2.11 | $0.00 | $0.35 | — | $2.90 |
| 2022 | $0.29 | −$0.78 | $0.00 | −$0.55 | — | $2.17 |
| 2023 | $0.77 | −$1.30 | $0.01 | −$0.95 | — | $1.49 |
| 2024 | $0.51 | −$2.28 | $0.00 | −$1.51 | — | $0.74 |
| 2025 | $1.86 | $1.35 | $0.01 | −$0.04 | — | $2.72 |